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ORIGINAL ARTICLE
CK2 abrogates the inhibitory effects of PRH/HHEX on
prostate cancer cell migration and invasion and acts through
PRH to control cell proliferation
YH Siddiqui1, RM Kershaw2, EH Humphreys2, EM Assis Junior1, S Chaudhri3, P-S Jayaraman2 and K Gaston1
PRH/HHEX (proline-rich homeodomain protein/haematopoietically expressed homeobox protein) is a transcription factor that
controls cell proliferation, cell differentiation and cell migration. Our previous work has shown that in haematopoietic cells, Protein
Kinase CK2-dependent phosphorylation of PRH results in the inhibition of PRH DNA-binding activity, increased cleavage of PRH by
the proteasome and the misregulation of PRH target genes. Here we show that PRH and hyper-phosphorylated PRH are present in
normal prostate epithelial cells, and that hyper-phosphorylated PRH levels are elevated in benign prostatic hyperplasia, prostatic
adenocarcinoma, and prostate cancer cell lines. A reduction in PRH protein levels increases the motility of normal prostate epithelial
cells and conversely, PRH over-expression inhibits prostate cancer cell migration and blocks the ability of these cells to invade an
extracellular matrix. We show that CK2 over-expression blocks the repression of prostate cancer cell migration and invasion by PRH.
In addition, we show that PRH knockdown in normal immortalised prostate cells results in an increase in the population of cells
capable of colony formation in Matrigel, as well as increased cell invasion and decreased E-cadherin expression. Inhibition of CK2
reduces PRH phosphorylation and reduces prostate cell proliferation but the effects of CK2 inhibition on cell proliferation are
abrogated in PRH knockdown cells. These data suggest that the increased phosphorylation of PRH in prostate cancer cells increases
both cell proliferation and tumour cell migration/invasion.
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INTRODUCTION
The transcription factor PRH/HHEX (proline-rich homeodomain
protein/haematopoietically expressed homeobox protein) is
required during embryogenesis for the development of several
organs including the heart, thyroid, pancreas and haematopoietic
compartment (reviewed by Souﬁ and Jayaraman1). In the adult,
PRH is expressed in multiple epithelial tissues and in haemato-
poietic cells. We have shown that PRH binds to speciﬁc DNA
sequences near target genes including Vegfa and the VEGF
receptor genes Vegfr-1 and Vegfr-2.2 Similarly, PRH directly
regulates the CD105 gene encoding the TGFβ co-receptor protein
Endoglin,3 and Goosecoid, a gene encoding a transcription
factor that induces epithelial-mesenchymal transition in multiple
cancer cell types.4,5 PRH also regulates gene expression via
protein–protein interactions with multiple transcription factors
including c-Myc6 and SOX13.7 In addition, PRH regulates gene
expression at the post-transcriptional level via an interaction with
translation initiation factor eIF4E.8 Aberrant subcellular localisation
of the PRH protein is associated with chronic myeloid leukaemia
and some types of acute myeloid leukaemia, as well as with breast
cancer and thyroid cancer.8–11
Our previous work has shown that in chronic myeloid leukaemia
cells PRH activity is controlled by Protein Kinase CK2 (Casein
Kinase 2).12–14 CK2 is a ubiquitously expressed serine/threonine
kinase important in the regulation of cell proliferation and cell
stress responses.15 CK2 activity is increased markedly in benign
prostatic hyperplasia (BPH) and prostatic adenocarcinoma.16 The
CK2 tetramer comprises two regulatory β-subunits and two
catalytic α-subunits. PRH interacts with the β-subunit of CK2 and
is a target for phosphorylation by the α-subunit. Phosphorylation
of PRH by CK2 results in the inactivation of PRH DNA-binding
activity as well as proteasomal processing of hyper-phos-
phorylated PRH (pPRH) and the production of a pPRH fragment
that inhibits the activity of full-length PRH.12,13 Downregulation of
PRH activity in chronic myeloid leukaemia cells by CK2 results in
the de-repression of Vegfa and VEGF receptor genes and thereby
promotes cell survival.13 CK2 phosphorylates two serine residues
in PRH (S163 and S177)12 and the replacement of serine with
cysteine at these positions in PRH S163C/S177C (PRH CC) prevents
phosphorylation by CK2. Although wild-type PRH represses Vegfr-
1 mRNA levels and CK2 over-expression counteracts this repres-
sion, CK2 over-expression is unable to counteract repression
brought about by PRH CC.13 The replacement of these serines
with glutamic acid in PRH S163E/S177E (PRH EE) produces a
phosphomimic that fails to bind DNA or repress Vegfr-1
transcription.13
In prostate and breast epithelial cells, the regulation of Endoglin
expression contributes to the control of cell motility by PRH.3
Moreover, over-expression of PRH in prostate cancer cells and
breast cancer cells inhibits cell migration and inhibits the ability of
prostate cancer cells to penetrate a layer of endothelial cells in
in vitro extravasation experiments.3 Here we show that PRH is
hyper-phosphorylated in BPH, prostatic adenocarcinoma and
prostate cancer cell lines and that PRH phosphorylation in
prostate cells is dependent on CK2 activity. PRH phosphorylation
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by CK2 inhibits prostate cancer cell migration and invasion.
Moreover, PRH regulates the proliferation of prostate cells and the
effects of CK2 inhibition on prostate cancer cell proliferation are
mediated in large part at least by changes in PRH phosphorylation.
RESULTS
PRH is phosphorylated by CK2 in prostate cells
We previously produced conformation-speciﬁc antibodies that
recognise preferentially either hypophosphorylated PRH (hypo-
PRH) or hyper-phosphorylated PRH (pPRH) and we used these
antibodies to show that the inhibition of CK2 in leukaemic cells
with speciﬁc inhibitors leads to loss of detection of pPRH.13 To
examine the expression and phosphorylation status of PRH in
prostate epithelial cells we made use of a normal immortalised
prostate epithelial cell line (PNT2-C2 cells17,18) and two well-
characterised prostate cancer cell lines (DU145 and PC3 cells).
Western blot analysis shows that hypo-PRH is present in all three
cell lines (Figure 1a). PRH levels were quantiﬁed in several
experiments by densitometry using Lamin A/C as a loading control
(Figure 1a, lower panel). Hypo-PRH levels are equal across the
three cell lines. In contrast, pPRH is weakly detected in PNT2-C2
cells and present at much higher levels in the prostate cancer cell
lines (Figure 1b). Quantiﬁcation relative to Tubulin as loading
control conﬁrms that pPRH is present at higher levels in the cancer
cell lines (Figure 1b, lower panel). To conﬁrm that CK2 is involved
in the phosphorylation of PRH in prostate cells we treated PNT2-
C2 cells for 72 h with the speciﬁc CK2 inhibitor TBB before western
blot analysis using pPRH-speciﬁc antibodies. Phosphorylated PRH
is present in the control cells but it is not detectable in the cells
treated with TBB (Figure 1c). Tubulin antibodies conﬁrm roughly
equal protein loading. Similarly, treatment of DU145 cells with TBB
or the CK2 inhibitor DMAT decreases PRH phosphorylation in a
dose-dependent manner (Figure 1d). In these cells treatment with
TBB also reduces phosphorylation of the unrelated CK2 target
protein XRCC1 conﬁrming that CK2 is inhibited (Supplementary
Fig S1). In summary, these data are in agreement with our
previous studies which showed that TBB and DMAT decrease PRH
phosphorylation in other cell types and that puriﬁed CK2 can
phosphorylate PRH in vitro.12 Moreover pPRH is present in the
prostate cancer cell lines at higher levels than in normal
immortalised prostate cells and CK2 activity is required for PRH
phosphorylation in prostate cells.
pPRH is elevated in BPH and prostatic adenocarcinoma
To conﬁrm that PRH is expressed in normal prostate tissue we
performed immunohistochemistry on ethically obtained tissue
sections from the University of Birmingham Biobank. In normal
prostate, staining for total PRH reveals predominantly cytoplasmic
PRH in the glandular epithelium with weak nuclear staining
(Figure 2a). In contrast, staining for pPRH reveals weak cytoplasmic
staining with little nuclear staining (Figure 2b). We conclude that
PRH is expressed in normal prostate epithelial cells in vivo and that
pPRH is also present in these cells. We next stained for PRH and
pPRH in BPH and prostatic adenocarcinoma sections (Figures 2c-f).
We scored PRH and pPRH cytoplasmic and nuclear staining
respectively according to intensity and the number of positively
staining cells in 14 BPH and prostatic adenocarcinoma sections
and seven normal prostate sections. The data summarised in
Figure 2i shows that nuclear pPRH staining is elevated in terms of
intensity and the percentage of positively staining cells in 5/5 BPH.
In contrast, in adenocarcinomas, the percentage of cells staining
positively for nuclear pPRH is increased (9/9) but nuclear staining
intensity is unchanged (5/9) or reduce (4/9). pPRH cytoplasmic
staining appears to be similar in normal, BPH and adenocarcino-
mas, although there is a reduction in staining intensity in some
BPH (3/5) and adenocarcinomas (4/9). Total PRH staining reveals
that ~ 70–100% of cells show cytoplasmic PRH in normal prostate,
BPH and adenocarcinoma. However, PRH cytoplasmic staining
intensity is increased in BPH (3/5) and adenocarcinoma (6/9)
compared with normal tissue (0/7). We conclude that nuclear
pPRH levels are elevated in BPH and prostatic adenocarcinoma
tissues and that total cytoplasmic PRH also appears to be elevated
in these tissues.
CK2 over-expression blocks the effects of PRH on cell migration
We showed previously that PRH over-expression inhibits the
migration of normal immortalised prostate PNT2-C2 cells and
prostate cancer cells and signiﬁcantly reduces the ability of DU145
Figure 1. PRH is hyper-phosphorylated in two prostate cancer cell
lines. (a, top) Representative western blot of hypophosphorylated
PRH in normal immortalised PNT2-C2 prostate cells and two
prostate cancer cell lines; DU145 and PC3. Hypo-PRH was stained
with an anti-hypo-PRH mouse polyclonal antibody and Lamin
A/C was used as a loading control. (bottom) Densitometric
analysis of hypo-PRH levels in three independent experiments.
(b, top) Representative western blot of hyper-phosphorylated PRH in
the cell lines from a. pPRH was stained with an anti-pPRH rabbit
polyclonal antibody and α-Tubulin was used as a loading control.
(bottom) Densitometric analysis of pPRH levels in three independent
experiments. DU145 *P= 0.002, PC3 *P= 0.015 (Student’s unpaired
t-test). (c) PNT2-C2 cells were treated with either 10% DMSO or
100 μM TBB in DMSO for 72 h. Western blotting was then used to
examine the levels of pPRH (as above). Representative of three
independent experiments. (d) DU145 cells were treated with (1)
50 μM DMAT, (2) 100 μM DMAT, (3) 50 μM TBB, (4) 100 μM TBB, in
DMSO, or (5) 10% DMSO alone for 72 h. Western blotting was then
used to examine the levels of pPRH (as above). Representative of
three independent experiments.
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cells to invade Matrigel.3 To determine whether the effects of
PRH on cell motility are blocked by CK2 activity we made use of a
non-phosphorylatable PRH mutant (PRH CC) that contains
cysteine residues at the positions that are targeted by CK2 for
phosphorylation (amino acids 163 and 177 in the PRH
homeodomain).13 Over-expression of wild-type PRH in DU145
cells results in the inhibition of cell motility in a transwell cell
migration assay (Figure 3a). However, co-expression of CK2α and
CK2β blocks the inhibitory effects of PRH over-expression
(Figure 3a). Over-expression of PRH CC also inhibits the migration
of DU145 cells (Figure 3a). However, co-expression of CK2α and
CK2β has no effect on the ability of PRH CC to inhibit cell
migration (Figure 3a). Western blot analysis conﬁrms that
exogenous PRH and PRH CC are expressed at roughly equivalent
levels in the transfected cells (Figure 3b). Over-expression of CK2α
and CK2β alone has no effect of the migration of DU145 cells in
this assay (Figure 3a) consistent with the hyperphosphorylation of
PRH seen in these cells (Figure 1b). We repeated these experi-
ments in PC3 cells and obtained identical results (Supplementary
Fig S2) conﬁrming that CK2 over-expression prevents PRH from
inhibiting prostate cancer cell migration and that this requires the
previously identiﬁed CK2 phosphorylation sites within the PRH
homeodomain.
To determine whether CK2 over-expression also inhibits the
effects of PRH on cell invasion we performed cell invasion assays
in which Matrigel is layered over the transwell ﬁlter.3 As expected,
DU145 cells are able to invade the Matrigel layer and migrate
through the transwell ﬁlter (Figure 3c). However, while over-
expression of PRH inhibits cell invasion, co-expression of PRH with
CK2α and CK2β abrogates the inhibitory effects of PRH (Figure 3c).
Over-expression of CK2α and CK2β alone has no effect on the
invasive ability of DU145 cells in this assay (Figure 3c). Again this is
consistent with the hyperphosphorylation of endogenous PRH
seen in these cells (Figure 1b). We conclude that increasing CK2
levels also prevents exogenous PRH from inhibiting prostate
cancer cell invasion.
PRH knockdown induces cell migration and invasion and
downregulates E-cadherin expression
The data shown above suggest that PRH activity is compromised
in prostate cancer cells due to increased phosphorylation. To
investigate how loss of PRH activity alters the behaviour of normal
prostate epithelial cells we knocked down PRH in PNT2-C2 cells
using Prh shRNA (exactly as described previously3). PNT2-C2 cells
were transfected with either a scrambled vector control shRNA
plasmid or a combination of two PRH shRNA plasmids and
selected for 10 days in puromycin (Figure 4a). Knockdown of PRH
in PNT2-C2 cells resulted in increased cell migration in wound
closure assays (Figure 4c). This is not the result of any effects of
PRH knockdown on cell proliferation as the experiments were
performed in the presence of hydroxyurea to inhibit cell division.
Moreover, since over-expression of PRH in these cells resulted in
decreased cell migration (Figure 3a), this increase in cell migration
Figure 2. PRH and pPRH are present in normal prostate, BPH and prostate adenocarcinoma. Representative immunohistochemistry from
normal prostate (a, b), BPH (c and d), and prostate adenocarcinoma (e, f) stained for total PRH using the M6 monoclonal antibody at 1:200
dilution (a, c, e) and pPRH using the YKN5 antibody at 1:750 dilution (b, d, f) as described in the text, and counterstained using Mayers
haematoxylin. (g, h) Normal tissue stained using mouse and rabbit IgG, respectively (×40 magniﬁcation). (i) A summary of the
immunohistochemistry data for pPRH (YKN5) and PRH (M6) staining presented as the percentage of cells/nuclei that stain and the intensity of
staining. AC, adenocarcinoma (with Gleason score); NA, not available.
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is unlikely to result from any off-target effects of the PRH shRNA.
Surprisingly constitutive knockdown of PRH in PNT2-C2 cells also
resulted in increased invasion (Figure 4d). This indicates that the
PRH knockdown cells have a mesenchymal phenotype and
suggests that the loss of PRH may alter cell-cell adhesion. In
agreement with this hypothesis, the PNT2-C2 PRH KD cells express
less E-cadherin protein compared with controls (Figures 4e and f).
PRH regulates prostate cell proliferation
To examine the effects of PRH on prostate cell proliferation, we
made use of a previously characterised recombinant adenovirus
expressing Myc-tagged PRH. PNT2-C2 and DU145 cells were
infected with either a control adenovirus encoding β-galactosi-
dase or the Myc-PRH adenoviral expression vector (Ad.PRH). The
number of viable cells was then determined at increasing time
points post infection using MTT assays. The MTT assay gives a
quantitative analysis of cell number and is therefore superior to
qualitative cell viability assays. In both cell lines, PRH over-
expression results in a signiﬁcant reduction in the number of
viable cells (Figures 5a and b). Western blot analysis conﬁrms the
expression of Myc-tagged PRH (Figure 5c). To conﬁrm that PRH
regulates prostate cell proliferation we made use of the PNT2-C2
PRH KD cells described above. The proliferation of PNT2-C2 PRH
KD cells and control cells was assayed using bromodeoxyuridine
(BrdU) incorporation assays. Control cells and PRH knockdown
cells were incubated with BrdU for 15 h and the cells were then
ﬁxed and stained with an anti-BrdU antibody. The percentage of
BrdU-positive cells increases from ~ 15% in the control population
to ~ 75% in PRH knockdown population (Figure 5d,e). These
results demonstrate that PRH over-expression inhibits prostate cell
proliferation, while PRH knockdown increases the proliferation of
PNT2-C2 cells. Knockdown of PRH in DU145 was not performed
since these cells are effectively PRH-depleted due to increased
PRH phosphorylation and knockdown is therefore unlikely to
increase their proliferation.
To assess the role of PRH in an assay with more relevance to the
native tissue environment compared with a monolayer culture, we
next examined the effects of PRH knockdown on the formation of
spheroids in a colony formation assay. PNT2-C2 cells suspended in
Matrigel form spheroidal structures17 reminiscent of glandular
epithelium (Figure 6a). We plated equal numbers of PNT2-C2 cells
and PNT2-C2 PRH knockdown cells in Matrigel and counted
the number of spheroids formed after 14 days in culture. PRH
knockdown resulted in a signiﬁcant increase in the number of
spheroids formed (Figure 6b). Since each colony arises from a
single cell this indicates that the reduction in PRH levels results in
an increase in the number of colony forming cells present in the
PNT2-C2 population rather than from a change in cell prolifera-
tion. Interestingly, the diameter of the spheroids produced by the
PRH knockdown cells is unaltered (Figure 6c). Thus PRH knock-
down has little or no effect on spheroid growth from the initial
colony forming cell. In support of these conclusions ﬂow
cytometry showed a signiﬁcant increase in the number of CD44
+/CD133+ cells indicative of the self-renewing stem cell popula-
tion able to form colonies (Figure 6d). Thus robust knockdown of
PRH in these cells results in increased cell proliferation and an
increase in the number of cells capable of colony formation, as
well as increased invasion.
PRH mediates the effects of TBB on the proliferation of PNT2-C2
cells
CK2 activity is often elevated in cancer cells and CK2 inhibition has
been proposed as a novel treatment for prostate cancer.19 To
determine whether the inhibition of CK2 activity alters the
proliferation of PNT2-C2 cells and to investigate whether any
effects of CK2 inhibition are dependent on changes in PRH
phosphorylation, we treated control and PNT2-C2 PRH knockdown
cells with the CK2 inhibitor TBB. After 72 h, we determined the
number of viable cells using an MTT assay. Treatment of control
PNT2-C2 cells with TBB resulted in a signiﬁcant reduction in the
number of viable cells (Figures 6e, 1 and 2). This was accompanied
by the loss of pPRH (Figure 1c). As expected, untreated PNT2-C2
PRH knockdown cells proliferated more than untreated PNT2-C2
cells over 72 h resulting in an increase in the number of viable cells
(Figures 6e, 1 and 3). However, treatment of the knockdown cells
with TBB had no effect on the number of viable cells (Figures 6e, 3
and 4). These data show that TBB treatment inhibits the
proliferation of PNT2-C2 cells and they suggest that changes in
PRH phosphorylation mediate the effects of TBB on these cells. It is
not possible to examine the effects of TBB on pPRH levels in the
PRH knockdown cells due to the low level of pPRH in these cells.
DISCUSSION
Aberrant intracellular localisation of PRH and/or altered PRH levels
have been observed in a number of disease states including
breast and thyroid cancer.10,11 This suggests that loss or reduction
Figure 3. CK2 abrogates the effects of PRH on prostate cancer cell
migration and invasion. (a) DU145 cells were transiently transfected
with a GFP expression vector alone (1) or cotransfected with vectors
expressing GFP, PRH or PRH CC and CK2 α- and β-subunits (2–6).
Twenty four hours post transfection the cells were plated in
Transwell chambers with a 2%:10% serum gradient. After 24 h the
green cells on the top and bottom surfaces of the ﬁlter were
counted using microscopy. Cells in 10 ﬁelds were counted in two
independent experiments to determine the percentage of migrated
cells. *P= 0.04. (b) The expression of Myc-tagged PRH and PRH CC
was examined using western blotting using an anti-Myc
monoclonal antibody with Lamin A/C as loading control. (c) Invasion
assays were performed as in a with a layer of Matrigel over the ﬁlter.
*P= 0.001.
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of PRH activity is associated with the increased proliferation of
breast and thyroid cancer cells. Our previous work showed that
phosphorylation of PRH by CK2 abolishes the DNA-binding activity
of PRH.12 We showed that this prevents PRH from regulating
transcription and abrogates the effects of PRH on the proliferation
of leukaemic cells.13 Here we have shown that nuclear pPRH is
increased in BPH and prostatic adenocarcinoma compared with
normal tissue and that pPRH levels are increased in prostate
cancer cell lines compared with normal immortalised prostate
epithelial cells. This suggests that in BPH and prostate cancer cells
PRH activity is inhibited by increased phosphorylation. Since PRH
inhibits the proliferation of prostate cells, this is in keeping with
the increased proliferation of BPH and prostate cancer cells. The
increase in pPRH is also in keeping with the reported increase in
CK2 activity in BPH and prostate cancer cells.16 Total PRH staining
is more intense in the cytoplasm in the BPH and adenocarcinoma
samples. This suggests that the cytoplasmic/nuclear distribution of
PRH is also altered in BPH and prostate adenocarcinoma and this
could also prevent PRH from regulating transcription.
Our recent work has shown that decreasing PRH levels in
normal prostate and breast epithelial cells can induce a migratory
phenotype.3 Moreover, PRH over-expression can inhibit the
migration of prostate and breast cancer cells, inhibit the invasion
of an extracellular matrix by these cells and inhibit the passage of
prostate cancer cells through a layer of normal human endothelial
cells in an in vitro extravasation assay.3 In leukaemic cells, PRH is
known to interact with the regulatory β-subunit of CK2 via a
protein–protein interaction and phosphorylation of PRH by CK2
results in PRH inactivation.12 Here we have shown that the
inhibition of CK2 in normal immortalised prostate epithelial PNT2-
C2 cells results in the loss of detection of pPRH. This suggests that
CK2 phosphorylates PRH in these cells. Over-expression of CK2 in
prostate cancer cells prevents PRH from inhibiting cell migration
and cell invasion but has no effect on the ability of a
non-phosphorylatable PRH mutant to inhibit cell migration. In
marked contrast, knockdown of PRH in non-invasive PNT2-C2 cells
induces cell migration and cell invasion and this is accompanied
by a decrease in E-cadherin protein levels. These data are
consistent with the observation of increased levels of pPRH in
migratory and invasive prostate cancer lines and in prostatic
adenocarcinoma. Taken together these observations suggest that
PRH controls the migratory behaviour of prostate cells and that
the increased PRH phosphorylation seen in the prostate cancer
cells contributes to their increased migration and invasion.
PRH is known to regulate cell proliferation in multiple cell types.1
PRH over-expression inhibits the proliferation of CML cells and we
have shown that over-expression of CK2 abrogates the negative
effects of PRH over-expression on these cells.2 Here we have shown
that PRH over-expression inhibits the proliferation of normal
immortalised prostate cells and prostate cancer cells. Moreover,
PRH knockdown increases the proliferation of normal immortalised
prostate cells. This suggests that PRH expression and PRH
phosphorylation are important in the control of prostate cell
proliferation as well as prostate cell migration. In normal immorta-
lised prostate cells knockdown of PRH increases the number of cells
that are capable of forming spheroids in Matrigel and the number of
cells displaying stem cell marker proteins (the CD44hi/CD133hi
population20,21). This suggests that the downregulation of PRH
Figure 4. PRH knockdown induces invasion and downregulates E-cadherin protein levels. (a) PNT2-C2 cells were transfected with plasmids
expressing either scrambled vector control shRNA or PRH shRNAs (PRH KD) and selected in media containing puromycin for 10 days. PRH
expression was then examined by western blotting using an anti-PRH mouse monoclonal antibody with Tubulin as loading control.
(b) Densitometric analysis of PRH protein levels at day 10 in puromycin selection in three independent experiments. *P= 0.001. (c) PNT2-C2
control cells and PRH KD cells were plated to produce conﬂuent monolayers that were then wounded with a pipette tip. After 24 h wound
width was measured at multiple locations and plotted as percentage wound width remaining (n= 3 independent control and KD cell lines,
Student’s t-test P= 0.01). (d) Transwell invasion of PNT2-C2 cells through Matrigel over 48 h, (n= 3 independent control and KD cell lines,
Student’s t-test P= 0.004). (e) Western blot showing E-cadherin levels in PNT2-C2 cells and PNT2-C2 PRH KD cells. Representation of n= 3.
(f) Quantitative analysis of E-cadherin expression in three independent PRH KD cell lines (n= 3, *Student’s t-test P= 0.03).
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increases the number of stem cells in the population capable of
colony formation. The resulting spheroids are identical in size to the
spheroids formed by control cells. Thus the controls that regulate
spheroid formation are not disrupted by the loss of PRH. Recent
evidence shows that spheroid formation and prostate cancer stem
cells are linked to E-cadherin expression and epithelial-mesenchymal
transition.22,23 Since knockdown of PRH in normal PNT2-C2 cells also
results in decreased E-cadherin expression, as well as increased
spheroid formation, we conclude that PRH normally regulates self-
renewal, cell proliferation and cell-cell contacts in these cells.
Moreover, phosphorylation of PRH in prostate tumour cells is likely
to contribute to their increased invasive potential and their
increased ability to form cancer stem cells.
In conclusion, we propose that in both normal and transformed
prostate epithelial cells PRH expression limits cell proliferation and
cell migration and invasion. Although treatment of normal
prostate cells with the speciﬁc CK2 inhibitor TBB results in a
decrease in cell proliferation, TBB has little or no effect on the
proliferation of PRH knockdown cells. This suggests that the
inhibitory effects of CK2 inhibitors on the proliferation of these
cells are mediated by PRH. This is important since CK2 activity is
elevated in prostate cancer and other disease states and the
inhibition of CK2 is a potential treatment for these diseases.
MATERIALS AND METHODS
Cell culture
PNT2-C2 cells were a kind gift from Professor Norman J Maitland
(University of York). PC3 and DU145 were obtained from the ATCC
(Manassas, VA, USA). Cells were cultured in RPMI-1640 supplemented with
10% fetal bovine serum, 2mM L-glutamine and 1% penicillin/streptomycin
and maintained in a humidiﬁed atmosphere at 37 °C and 5% CO2. In some
experiments cells were also incubated with TBB (4,5,6,7-tetrabromo-2-
azabenzimidazole) or DMAT (2-Dimethylamino-4,5,6,7-tetrabromo-1H-ben-
zimidazole) (Sigma, St Louis, MO, USA). Three dimensional culture of PNT2-
C2 cells was performed as described by Maitland.17 Cells were suspended
in growth media (6 × 104 cells/ml) then mixed with Matrigel (Sigma) on ice
in a 1:1 (v/v) ratio and plated into 24-well plates. The Matrigel was set by
incubating at 37 °C for 30 min, after which growth media was added to
each well and changed every 3 days. Images were obtained using a phase-
contrast Leica (Wetzlar, Germany) DMIRB inverted microscope at × 10
magniﬁcation, using the Image Acquisition software Volocity 5.5.1 (Perkin
Elmer, Akron, OH, USA). The diameter of the spheroids was measured using
ImageJ software (NIH, Bethesda, MD, USA).
Transient transfection and expression plasmids
Cells were transiently transfected using TransIT (Mirus, Madison, WI, USA)
according to the manufacturer’s protocol. The PRH expression vectors pMUG1-
Myc-PRH, pMUG1-Myc-PRH N187A, pMUG1-Myc-PRH F32E, pMUG1-Myc-PRH
S163C/S177C and pMUG1-Myc-PRH S163E/S177E have been described.13,24,25
The CK2 expression vectors pRc/CMV-CK2α-HA and pRc/CMV-CK2β-HA were a
kind gift from Professor D Litchﬁeld (University of Western Ontario). Plasmids
encoding short hairpin RNAs (shRNAs) shRNAPRH49, shRNAPRH51, and
control shRNA were supplied by Origene (Rockville, MD, USA).
Immunohistochemistry
Immunohistochemistry was performed on formalin-ﬁxed parafﬁn-
embedded human prostate tissues (normal, hyperplasia, low- or high-
grade carcinoma). Tissues were ethically obtained from the Queen
Elizabeth Hospital Birmingham pathology archive through the Human
Biobank Repository Centre. The tissues were stained with the Vector
ImmPress Excel anti-mouse Ig or anti-rabbit Ig peroxidase kits (MP-7602 or
MP-7601, respectively, Vector Laboratories (Burlingame, CA, USA) and
visualised with the ImmPact NovaRed peroxidase substrate (Vector
Laboratories) according to the manufacturer’s instructions. Staining was
performed as follows: tissues were dewaxed in xylene (PFM Medical,
Cologne, Germany) and then rehydrated in graded alcohols (VWR) and
then distilled water. Antigen retrieval was performed with high pH buffer
Figure 5. PRH inhibits the proliferation of normal immortalised prostate epithelial cells. (a) PNT2-C2 cells were infected with control
adenovirus (ﬁlled circles) or an adenovirus expressing Myc-tagged PRH (open circles) at an MOI of 50. The number of viable cells was
determined using an MTT assay at 24, 48 and 72 h post infection. Mean and s.d. n= 3 independent experiments each performed in triplicate.
(b) The experiment shown in a was repeated using DU145 cells. (c) Myc-PRH expression levels in the cells from a, b were determined as in
Figure 3b. (d) BrdU staining of control and PRH KD cells (×63 magniﬁcation). Representative BrdU-positive and -negative cells are indicated by
ﬁlled and empty arrowheads, respectively. The cells were counterstained using haematoxylin. (e) The percentage of BrdU incorporation. Mean
and s.d., n= 3. *P= 0.002.
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(Vector Laboratories) and the sections were incubated in Bloxall solution
(Vector Laboratories) for 10 min at 20 °C to block endogenous peroxidase
activity and then in 2.5% horse serum (Vector Laboratories) for 20 min at
20 °C. The primary antibodies (mouse anti-human PRH (M6) 1:200 or rabbit
anti-human PRH (YKN5) 1:750) diluted in 2.5% horse serum were added to
the sections and incubated overnight at 4 °C. The sections were then
washed in Tris-buffered saline pH 7.2 (Pierce, Paisley, UK) for 5 min and
incubated with ampliﬁer antibody for 15 min at 20 °C. After washing in
Tris-buffered saline pH 7.2 for 5 min the sections were incubated with the
ImmPress Excel tertiary antibody for 30 min at 20 °C. The sections were
washed in Tris-buffered saline pH 7.2 for 5 min and the NovaRed
peroxidase substrate was added for 5 min. The reaction was stopped by
washing in distilled water for 5 min and the sections counterstained using
Mayers haematoxylin (PFM Medical) for 30 s. The sections were mounted
using DPX (Cell Path, Mochdre, UK) and left to dry before being visualised
on a Zeiss (Oberkochen, Germany) microscope. Images were acquired
using AxioVision v4.3 software (Zeiss).
Western blot analysis
Whole cell extracts were prepared in TES buffer (1% SDS, 2 mM EDTA,
20 mM Tris-HCl pH 7.4) as described previously.3 Antibodies that recognise
total PRH, hyper-phosphorylated PRH and hypophosphorylated PRH have
been described previously.13 Lamin A/C (H-110) and Tubulin (H-235)
antibodies were from Santa-Cruz (Dallas, TX, USA). The antibody for
phosphoXRCC1 was a kind gift from Dr Grant Stewart (University of
Birmingham). Densitometric analysis was performed using Quantity One
4.6 software (BioRad, Hercules, CA, USA).
Cell migration and invasion assays
Chemotaxis assays were performed by seeding cells onto 8 μm Boyden
chambers (Greiner Bio-One, Frickenhausen, Germany) in RPMI-1640 with 2%
fetal bovine serum. The chambers were placed into 24-well plates containing
RPMI-1640 with 10% fetal bovine serum to create a serum gradient. After
incubation in a humidiﬁed atmosphere at 37 °C and 5% CO2 for 24 or 48 h
the cells were ﬁxed with 4% paraformaldehyde (Fisher) and stained with
2 μg/ml bisbenzimide (Sigma). Cells on the top and bottom of the
membrane were counted using a Leica Q550 inverted epiﬂuorescence
microscope or Zeiss Axioplan 2. Invasion assays were performed as above
except that Matrigel (BD Biosciences) was added to the chambers and left at
37 °C for 1 h to solidify before seeding. For wound closure assays a conﬂuent
layer of cells was wounded using a pipette tip before fresh culture media
containing 2 μM hydroxyurea (Sigma) was added to block cell proliferation.
After 24 h phase-contrast images were obtained at × 100 magniﬁcation,
using Axiovision with an inverted bright-ﬁeld microscope and the migrated
distance was measured at 20 points along the wound edge using ImageJ.
MTT assays
MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) cell
viability assays were performed as described previously.13 Quantiﬁcation
was carried out on a VERSAmax microplate reader (Molecular Devices,
Sunnyvale, CA, USA) at 540 nm using SOFTmax PRO 3.1.2 (Molecular
Devices, San Diego, CA, USA). In PRH over-expression experiments cells
were treated with either empty adenovirus or an adenovirus expressing
Myc-tagged PRH 26 at a multiplicity of infection (MOI) of 50 and incubated
in a humidiﬁed atmosphere at 37 °C and 5% CO2 for up to 72 h.
BrdU incorporation assays
Cells growing on cover slips were incubated in media containing 10 μM
BrdU (Sigma) for 15 h. After ﬁxation in 4% paraformaldehyde (10 min at
20 °C) the cells were incubated with hydrogen peroxide for 5 min at 4 °C.
The cells were then incubated with 62 500 Units Benzonase (Sigma) and
1 mM MgCl2 at 37 °C for 2 h with shaking. The cells were then incubated
with an anti-BrdU antibody (1:500, Sigma B8434) in 1% bovine serum
albumin/phosphate-buffered saline overnight at 4 °C followed by incuba-
tion with horse anti-mouse biotin conjugate (1:200, Vector Laboratories) in
1% bovine serum albumin/phosphate-buffered saline for 90 min on a
shaker at 37 °C and incubation with streptavidin-horseradish peroxidase
(1:200, Sigma) in 1% bovine serum albumin/phosphate-buffered saline for
30 min with shaking. Diaminobenzidine (DAB) solution (Sigma) was then
added and incubated for 10 min at 20 °C. The cells were counterstained
using haematoxylin and mounted with Vectamount Permanent Mounting
medium (Vector Laboratories). Ten ﬁelds of view per slide were imaged
using a Leica DM LB2 upright ﬂuorescence microscope.
Flow cytometry
For ﬂow cytometry cells were resuspended in phosphate-buffered saline
and stained for 15 min with CD44-PE (BD Biosciences G44-26) and CD133-
APC (Miltenyi Biotec, Bisley, UK, AC133) antibodies. Samples were analysed
using a FACS Analyser Cyan ADP (Beckman Coulter, Brea, CA, USA). Dead
cells were gated out and at least 10,000 live events were analysed using
Summit software v4 (Beckman Coulter).
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Figure 6. PRH knockdown increases the number of colony forming
cells. PNT2-C2 cells and PNT2-C2 PRH KD cells were mixed with
Matrigel 1:1 v/v (on ice) and plated in 0.5 ml aliquots in a 24-well
plate. After 15 days in culture phase-contrast images were taken
using a Leica DMPXA/DMRBE microscope with Volocity 5.5.1.
A representative PNT2-C2 spheroid is shown (a) at × 100 magniﬁca-
tion. The number of spheroids in 10 ﬁelds (b) and their diameter (c)
was determined using ImageJ. Mean and s.d. are shown in each case
(n= 3 independent knockdowns). *P= 0.04 and ns—not signiﬁcant.
(d) The percentage increase in the CD44hi/CD133hi population
determined using ﬂow cytometry. Means and s.d. for n= 3. *P= 0.01.
(e) Control scrambled vector control shRNA plasmid cells (empty
bars) and PRH knockdown cells (ﬁlled bars) were treated with 10%
DMSO or 100 μM TBB in DMS0 for 72 h. The number of viable cells
was then determined using MTT assays. Mean and s.d., n= 3.
*P= 0.01 and ns, not signiﬁcant.
CK2 regulates PRH/HHEX in prostate cells
YH Siddiqui et al
7
Oncogenesis (2017), 1 – 8
AUTHOR CONTRIBUTIONS
PSJ and KG conceived the experiments, assisted with the data analysis and
wrote the manuscript. YS and EM generated prostate cancer cell lines, carried
out the in vitro assays and commented on the manuscript. RMK performed the
ﬂow cytometry and commented on the manuscript. EHH and SC performed the
IHC and analysis and commented on the manuscript.
REFERENCES
1 Souﬁ A, Jayaraman PS. PRH/Hex: an oligomeric transcription factor and multi-
functional regulator of cell fate. Biochem J 2008; 412: 399–413.
2 Noy P, Williams H, Sawasdichai A, Gaston K, Jayaraman PS. PRH/Hhex controls cell
survival through coordinate transcriptional regulation of vascular endothelial
growth factor signaling. Mol Cell Biol 2010; 30: 2120–2134.
3 Kershaw R, Siddiqui Y, Roberts D, Jayaraman PS, Gaston K. PRH/Hhex inhibits the
migration of breast and prostate epithelial cells through direct transcriptional
regulation of Endoglin. Oncogene 2014; 33: 5592–5600.
4 Williams H, Jayaraman PS, Gaston K. DNA wrapping and distortion by an oligo-
meric homeodomain protein. J Mol Biol 2008; 383: 10–23.
5 Brickman JM, Jones CM, Clements M, Smith JC, Beddington RS. Hex is a
transcriptional repressor that contributes to anterior identity and suppresses
Spemann organiser function. Development 2000; 127: 2303–2315.
6 Marﬁl V, Blazquez M, Serrano F, Castell JV, Bort R. Growth-promoting and
tumourigenic activity of c-Myc is suppressed by Hhex. Oncogene 2014; 34:
3011–3022.
7 Marﬁl V, Moya M, Pierreux CE, Castell JV, Lemaigre FP, Real FX et al. Interaction
between Hhex and SOX13 modulates Wnt/TCF activity. J Biol Chem 2010; 285:
5726–5737.
8 Topisirovic I, Culjkovic B, Cohen N, Perez JM, Skrabanek L, Borden KL. The proline-
rich homeodomain protein, PRH, is a tissue-speciﬁc inhibitor of eIF4E-dependent
cyclin D1 mRNA transport and growth. EMBO J 2003; 22: 689–703.
9 Jankovic D, Gorello P, Liu T, Ehret S, La SR, Desjobert C et al. Leukemogenic
mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia.
Blood 2008; 111: 5672–5682.
10 D'Elia AV, Tell G, Russo D, Arturi F, Puglisi F, Manﬁoletti G et al. Expression and
localization of the homeodomain-containing protein HEX in human
thyroid tumors. J Clin Endocrinol Metab 2002; 87: 1376–1383.
11 Puppin C, Puglisi F, Pellizzari L, Manﬁoletti G, Pestrin M, Pandolﬁ M et al. HEX
expression and localization in normal mammary gland and breast carcinoma.
BMC Cancer 2006; 6: 192.
12 Souﬁ A, Noy P, Buckle M, Sawasdichai A, Gaston K, Jayaraman PS. CK2 phos-
phorylation of the PRH/Hex homeodomain functions as a reversible switch for
DNA binding. Nucleic Acids Res 2009; 37: 3288–3300.
13 Noy P, Sawasdichai A, Jayaraman PS, Gaston K. Protein kinase CK2 inactivates
PRH/Hhex using multiple mechanisms to de-repress VEGF-signalling genes and
promote cell survival. Nucleic Acids Res 2012; 40: 9008–9020.
14 Noy P, Gaston K, Jayaraman PS. Dasatinib inhibits leukaemic cell survival by
decreasing PRH/Hhex phosphorylation resulting in increased repression of VEGF
signalling genes. Leukemia Res 2012; 36: 1434–1437.
15 Litchﬁeld DW. Protein kinase CK2: structure, regulation and role in cellular deci-
sions of life and death. Biochem J 2003; 369: 1–15.
16 Yenice S, Davis AT, Goueli SA, Akdas A, Limas C, Ahmed K. Nuclear casein kinase 2
(CK-2) activity in human normal, benign hyperplastic, and cancerous prostate.
Prostate 1994; 24: 11–16.
17 Lang SH, Sharrard RM, Stark M, Villette JM, Maitland NJ. Prostate epithelial cell
lines form spheroids with evidence of glandular differentiation in three-
dimensional Matrigel cultures. Br J Cancer 2001; 85: 590–599.
18 Berthon P, Cussenot O, Hopwood L, Leduc A, Maitland N. Functional expression of
sv40 in normal human prostatic epithelial and ﬁbroblastic cells - differentiation
pattern of nontumorigenic cell-lines. Int J Oncol 1995; 6: 333–343.
19 Trembley JH, Wang G, Unger G, Slaton J, Ahmed K. Protein kinase CK2 in health
and disease: CK2: a key player in cancer biology. Cell Mol Life Sci 2009; 66:
1858–1867.
20 Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identiﬁcation of
tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946–10951.
21 Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel
marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117: 3539–3545.
22 Deep G, Jain AK, Ramteke A, Ting H, Vijendra KC, Gangar SC et al. SNAI1 is critical
for the aggressiveness of prostate cancer cells with low E-cadherin. Mol Cancer
2014; 13: 37.
23 Li P, Yang R, Gao WQ. Contributions of epithelial-mesenchymal transition and
cancer stem cells to the development of castration resistance of prostate cancer.
Mol Cancer 2014; 13: 55.
24 Desjobert C, Noy P, Swingler T, Williams H, Gaston K, Jayaraman PS. The PRH/Hex
repressor protein causes nuclear retention of Groucho/TLE co-repressors. Biochem
J 2009; 417: 121–132.
25 Swingler TE, Bess KL, Yao J, Stifani S, Jayaraman PS. The proline-rich home-
odomain protein recruits members of the Groucho/Transducin-like enhancer of
split protein family to co-repress transcription in hematopoietic cells. J Biol Chem
2004; 279: 34938–34947.
26 Souﬁ A, Smith C, Clarke AR, Gaston K, Jayaraman PS. Oligomerisation of the
developmental regulator proline rich homeodomain (PRH/Hex) is mediated
by a novel proline-rich dimerisation domain. J Mol Biol 2006; 358: 943–962.
Oncogenesis is an open-access journal published by Nature Publishing
Group. This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third partymaterial in this article are included
in the article’s Creative Commons license, unless indicated otherwise in the credit line; if
the material is not included under the Creative Commons license, users will need to
obtain permission from the license holder to reproduce the material. To view a copy of
this license, visit http://creativecommons.org/licenses/by/4.0/
© The Author(s) 2017
Supplementary Information accompanies this paper on the Oncogenesis website (http://www.nature.com/oncsis)
CK2 regulates PRH/HHEX in prostate cells
YH Siddiqui et al
8
Oncogenesis (2017), 1 – 8
